Oct 25, 2006
By:
Beth Herskovits
Merck's Januvia has a head start, but Novartis isn't sitting idle.
|
Oct 11, 2006
By:
Beth Herskovits
Drug giant beefs up early-stage R&D, moving into Genentech's turf.
|
Oct 11, 2006
By:
Beth Herskovits
After axing oncology, Gilead says it's ready for new therapeutic areas.
|
Oct 11, 2006
By:
Beth Herskovits
JAMA study questions effectiveness of popular antidepressants.
|
|
Mifepristone is best known as an abortion drug. But it appears to be on the verge of a second career—treating a severe form of major depression.
Oct 1, 2006
By:
Beth Herskovits
Most people have never heard of psychotic depression, but they are familiar with the case of Andrea Yates, who tragically murdered her children during an episode of the disease.
|
Sep 27, 2006
By:
Beth Herskovits
The Part D donut hole has arrived, and pharma is scrambling to maintain brand loyalty.
|
Sep 27, 2006
By:
Beth Herskovits
The recent settlement between branded and generic companies offers a 'win-win' approach to patent challenges.
|
Sep 27, 2006
By:
Beth Herskovits
A new, faster recipe for drug development: Chat up regulators. Outsource where you can. And know when to let go.
|
Sep 13, 2006
By:
Beth Herskovits
Company-commissioned report exonerates senior managers, points fingers at sales team
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
